Dacryocystitis Medical Services in China

Dacryocystitis is an inflammatory condition of the lacrimal sac, typically caused by obstruction of the nasolacrimal duct—most commonly due to chronic infection, anatomical narrowing, or prior trauma. It presents with epiphora (excessive tearing), swelling and tenderness over the medial canthus, purulent discharge upon pressure over the lacrimal sac, and sometimes fever in acute cases. If left untreated, it may progress to abscess formation, orbital cellulitis, or systemic infection. Diagnosis relies on clinical evaluation, dye disappearance test, lacrimal irrigation, and imaging such as dacryoendoscopy or CT dacryocystography to localize obstruction. Treatment ranges from conservative measures (antibiotics, warm compresses) for acute episodes to definitive surgical intervention—primarily dacryocystorhinostomy (DCR)—to restore tear drainage. Endoscopic DCR has become the gold standard, offering high success rates (>90%) with minimal scarring and faster recovery.

China offers distinct advantages for international patients seeking treatment for dacryocystitis: world-class ophthalmology centers equipped with cutting-edge endoscopic and laser-assisted DCR platforms; highly trained specialists fluent in English and experienced in managing complex, recurrent, or pediatric cases; significantly lower costs (30–50% less than Western countries) without compromising quality; and streamlined medical tourism support—including visa assistance, multilingual coordination, and postoperative follow-up via telemedicine. Leading institutions like Beijing Tongren Hospital and Shanghai Eye & ENT Hospital perform over 2,000 DCR procedures annually, with published success rates exceeding 94% and documented outcomes in international journals. Numerous verified cases include successful revision DCR in patients previously failed elsewhere and minimally invasive endonasal DCR in elderly or comorbid individuals.

Treatment Options & Itemized Cost Breakdown for Dacryocystitis (Lacrimal Sac Inflammation)

Non-Surgical / Conservative Management

*Indicated for acute, mild-to-moderate cases without abscess formation or systemic toxicity.*

• •Topical Antibiotics (e.g., levofloxacin ophthalmic solution): ¥45–¥80 ($6–$11) per bottle
• •Oral Antibiotics (e.g., amoxicillin-clavulanate 625 mg × 7 days): ¥90–¥160 ($12–$22)
• •Warm Compresses & Lacrimal Sac Massage: No direct cost; instruction included in outpatient visit
• •Outpatient Evaluation & Culture/Sensitivity Testing: ¥120–¥200 ($16–$27), includes slit-lamp exam, lacrimal irrigation, and bacterial culture

Surgical / Procedural Interventions

*Required for chronic/recurrent cases, dacryocele, or failure of medical therapy. Performed by Ophthalmology Department.*

• •Dacryocystorhinostomy (DCR) — *Gold standard*:

- *Endoscopic DCR* (preferred): ¥8,200–¥12,500 ($1,120–$1,710) - *External DCR*: ¥6,800–¥9,400 ($930–$1,290)

• •Preoperative Workup (mandatory): Nasolacrimal endoscopy + CT dacryocystography + blood tests (CBC, coagulation, ECG): ¥1,450–¥2,100 ($200–$290)
• •Probing & Irrigation under Anesthesia (for infants <12 months): ¥1,800–¥2,600 ($250–$360), includes sedation

Special/Complex Condition Management

• •Acute Suppurative Dacryocystitis with Abscess: Incision & drainage + IV antibiotics (3-day inpatient stay): ¥4,900–¥7,300 ($670–$1,000), includes ICU-level monitoring if needed
• •Post-Traumatic or Post-Radiation Dacryocystitis: Requires custom silicone intubation + adjunctive mitomycin C: ¥10,800–¥14,200 ($1,480–$1,940)
• •Recurrent DCR Failure (>2 procedures): Endoscopic revision + conjunctivodacryocystorhinostomy (CDCR) with Jones tube: ¥13,500–¥17,600 ($1,850–$2,410)

Quick Selection Guide

• •Infants (<1 yr): Start with probing under anesthesia ($250–$360) — high success rate (>90%), lowest risk.
• •Adults, Mild Acute Episode: Oral + topical antibiotics + warm compresses ($18–$33 total) — avoid surgery unless recurrence.
• •Chronic (>6 mo), Working-Age Adult: Endoscopic DCR ($1,120–$1,710) — superior cosmesis, faster recovery, lower revision rate.
• •Elderly (>75 yr) or High-Risk Comorbidities (COPD, anticoagulation): External DCR ($930–$1,290) — more predictable anatomy, easier intraoperative control.
• •Budget-Constrained Patients: External DCR at public Grade 3A hospital ($930) — same long-term efficacy as endoscopic, lower facility fee.
• •Recurrent/Complex Cases: CDCR with Jones tube ($1,850–$2,410) — definitive solution when standard DCR fails due to severe scarring or canalicular loss.